A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Denintuzumab mafodotin (Primary)
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Seattle Genetics
- 29 Jun 2017 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Results (n=62) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2015 Results (n = 62) published in a Seattle Genetics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History